中山康方生物医药有限公司 Mediaroom

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announc...

2026-03-16 10:05 1387

Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced...

2026-03-05 10:26 4035

Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401...

2026-03-04 21:52 4195

Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the Nati...

2026-02-11 17:01 6080

Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescim...

2026-02-06 10:26 6898

Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the interna...

2026-01-29 12:51 4854

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New ...

2026-01-19 19:24 6287

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real...

2026-01-14 11:54 5463

Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study

HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical P...

2026-01-07 10:50 5372

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced...

2025-12-12 10:31 4582

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced...

2025-12-11 09:53 2565

Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced ...

2025-12-09 15:50 1962

Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced ...

2025-12-09 10:02 2350

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced ...

2025-12-07 14:18 2049

Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a no...

2025-11-17 10:29 1833

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that t...

2025-11-10 19:39 1245

Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecifi...

2025-11-03 12:12 1425

Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final a...

2025-10-19 23:42 1878

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.000...

2025-10-19 23:37 1708

HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation

HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaki...

2025-10-16 12:15 1609

Latest News